A Trial of Validation and Restoration of Immune Dysfunction in Severe Infections and Sepsis
Status:
Completed
Trial end date:
2019-12-31
Target enrollment:
Participant gender:
Summary
The aim of the study is to conduct one RCT of personalized immunotherapy in sepsis targeting
patients who lie either on the predominantly hyper-inflammatory arm or on the predominantly
hypo-inflammatory arm of the spectrum of the host response. These patients will be selected
by the use of a panel of biomarkers and laboratory findings and they will be randomly
allocated to placebo or immunotherapy treatment according to their needs.
Phase:
Phase 2
Details
Lead Sponsor:
Hellenic Institute for the Study of Sepsis
Treatments:
Interferon-gamma Interferons Interleukin 1 Receptor Antagonist Protein